Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Both ...

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...

B Verve Therapeutics (VERV) acquisition offers investors a 70%+ premium. See why I think this deal is beneficial to both ...

Lilly and Novo Nordisk NVO presently dominate the market. Mounjaro and Zepbound face strong competition from Novo Nordisk’s semaglutide medicines, Ozempic for diabetes and Wegovy for obesity.

The therapy is facing stiff competition, biosimilar and otherwise, that is eating into its market share ... only approved medicine that does that is Zepbound, the weight loss therapy marketed ...

Part of the appeal of amylin analogs is the potential to drive weight loss without causing the same level of tolerability problems as GLP-1 receptor agonists. Lilly reported relatively low rates of ...

Eli Lilly ( LLY 0.90%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following ...

Novo Nordisk A/S shares are staging a comeback after a tumultuous year for the maker of Ozempic and Wegovy. The stock is up ...

Discover why Hims & Hers is leading the telehealth market with strong growth, a loyal user base, and expansion into new ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Millions of Americans use GLP-1s, and many have relied on versions produced by compounding pharmacies because of the high monthly costs for brand names like Mounjaro and Zepbound.